Annals of internal medicine
-
Racial and ethnic disparities in incidence and mortality are well documented for many types of cancer. As a result, there is understandable policy and clinical interest in race- and ethnicity-based clinical screening guidelines to address cancer health disparities. Despite the theoretical benefits, such proposals do not typically address associated ethical considerations. ⋯ Given the ethical considerations, the practical application of race and ethnicity in cancer screening is most relevant in multicultural countries if and only if alternative proxies are not available. Even in those instances, policymakers and clinicians should carefully address the ethical considerations within the historical and cultural context of the intended population. Further research on alternative proxies, such as social determinants of health and culturally based characteristics, could provide more adequate factors for risk stratification.
-
Meta Analysis
In sepsis or septic shock, prolonged vs. intermittent infusion of β-lactam antibiotics reduces mortality at 90 d.
Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of β-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. JAMA. 12 June 2024. [Epub ahead of print.] 38864162.
-
Comment Randomized Controlled Trial
After ACS, telemedicine-based care with remote patient monitoring vs. usual care reduced hospital readmissions at 6 mo.
Alshahrani NS, Hartley A, Howard J, et al. Randomized trial of remote assessment of patients after an acute coronary syndrome. J Am Coll Cardiol. 2024;83:2250-2259. 38588928.
-
Comment Randomized Controlled Trial
In sepsis, continuous and intermittent infusion of β-lactam antibiotics did not differ for mortality at 90 d.
Dulhunty JM, Brett SJ, De Waele JJ, et al; BLING III Study Investigators. Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial. JAMA. 12 June 2024. [Epub ahead of print.] 38864155.
-
Comment Randomized Controlled Trial
In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.